Jérôme Alexandre

8.7k total citations · 1 hit paper
89 papers, 7.1k citations indexed

About

Jérôme Alexandre is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jérôme Alexandre has authored 89 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Jérôme Alexandre's work include Cancer Treatment and Pharmacology (14 papers), Renal cell carcinoma treatment (12 papers) and Ovarian cancer diagnosis and treatment (12 papers). Jérôme Alexandre is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Renal cell carcinoma treatment (12 papers) and Ovarian cancer diagnosis and treatment (12 papers). Jérôme Alexandre collaborates with scholars based in France, United States and Spain. Jérôme Alexandre's co-authors include Peng Huang, Dunyaporn Trachootham, François Goldwasser, Frédéric Batteux, Christiane Chéreau, Carole Nicco, Bernard Weill, Alexis Laurent, Weiqin Lu and Hélène Pelicano and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Jérôme Alexandre

87 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

2009 4.5k citations Jérôme Alexandre et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jérôme Alexandre France	25	3.5k	1.5k	1.2k	1.1k	808	89	7.1k
Dunyaporn Trachootham Thailand	19	4.6k 1.3×	1.0k 0.7×	1.4k 1.1×	1.4k 1.3×	902 1.1×	52	8.4k
Ivan Spasojević United States	55	4.0k 1.1×	1.3k 0.9×	891 0.7×	1.1k 1.0×	1.9k 2.4×	228	9.6k
Giorgio Minotti Italy	45	2.9k 0.8×	2.7k 1.8×	543 0.4×	489 0.5×	573 0.7×	152	9.7k
Yan Luo China	40	2.3k 0.7×	765 0.5×	719 0.6×	523 0.5×	825 1.0×	201	6.2k
Isaac S. Harris United States	23	6.0k 1.7×	1.3k 0.9×	1.0k 0.9×	3.6k 3.4×	589 0.7×	39	9.5k
Tian Xie China	42	3.4k 1.0×	652 0.4×	547 0.5×	1.2k 1.1×	312 0.4×	211	6.2k
Peter Tsvetkov Israel	27	3.3k 0.9×	897 0.6×	563 0.5×	1.3k 1.2×	457 0.6×	40	5.5k
Fátima Baltazar Portugal	47	3.7k 1.1×	1.3k 0.9×	539 0.4×	3.0k 2.8×	306 0.4×	174	6.9k
José M. Estrela Spain	44	3.1k 0.9×	596 0.4×	472 0.4×	648 0.6×	341 0.4×	88	6.5k
Fei Yan China	43	2.5k 0.7×	574 0.4×	1.2k 1.0×	838 0.8×	602 0.7×	202	5.4k

Countries citing papers authored by Jérôme Alexandre

Since Specialization

Citations

This map shows the geographic impact of Jérôme Alexandre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Alexandre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Alexandre more than expected).

Fields of papers citing papers by Jérôme Alexandre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Alexandre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Alexandre. The network helps show where Jérôme Alexandre may publish in the future.

Co-authorship network of co-authors of Jérôme Alexandre

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Alexandre. A scholar is included among the top collaborators of Jérôme Alexandre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Alexandre. Jérôme Alexandre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boudou‐Rouquette, Pascaline, Jennifer Arrondeau, Laure Hirsch, et al.. (2024). Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study. Clinical Nutrition ESPEN. 64. 44–50. 2 indexed citations

Arrondeau, Jennifer, Anne Jouinot, Pascaline Boudou‐Rouquette, et al.. (2023). Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors. Clinical Nutrition. 42(6). 944–953. 10 indexed citations

Puszkiel, Alicja, Pascaline Boudou‐Rouquette, Jérôme Alexandre, et al.. (2023). Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection. Cancer Chemotherapy and Pharmacology. 93(2). 169–175. 1 indexed citations

Courlet, Perrine, Athina Stravodimou, Haïthem Chtioui, et al.. (2022). Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics. 14(7). 1317–1317. 6 indexed citations

Boudou‐Rouquette, Pascaline, Anne Jouinot, Nihel Khoudour, et al.. (2022). Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients. Pharmaceutics. 14(6). 1224–1224. 6 indexed citations

Bellesœur, Audrey, Anne Jouinot, Camille Tlemsani, et al.. (2021). Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. Cancer Chemotherapy and Pharmacology. 88(4). 741–751. 4 indexed citations

Colomba, Émeline, Grégoire Marret, Giulia Baciarello, et al.. (2020). Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. European Journal of Cancer. 129. 117–122. 11 indexed citations

Hirsch, Laure, Audrey Bellesœur, Pascaline Boudou‐Rouquette, et al.. (2019). The impact of body composition parameters on severe toxicity of nivolumab. European Journal of Cancer. 124. 170–177. 33 indexed citations

Jouinot, Anne, Jean-Philippe Durand, Pascaline Boudou‐Rouquette, et al.. (2019). Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. Clinical Nutrition. 39(6). 1893–1899. 26 indexed citations

10.

Blanchet, Benoı̂t, Mohammad Alyamani, Lisa Golmard, et al.. (2018). A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Pharmacological Research. 136. 56–61. 11 indexed citations

11.

Puszkiel, Alicja, Gaëlle Noé, Pascaline Boudou‐Rouquette, et al.. (2017). Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis. 139. 30–36. 37 indexed citations

12.

Bonnet, Clément, Pascaline Boudou‐Rouquette, Olivier Huillard, et al.. (2017). Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer Chemotherapy and Pharmacology. 79(5). 1051–1055. 16 indexed citations

13.

Bretagne, Marie, Pascaline Boudou‐Rouquette, Olivier Huillard, et al.. (2016). Inhibiteurs de tyrosine kinase ciblant l’angiogenèse et sujets âgés : tolérance, évaluation pré-thérapeutique et gestion des effets indésirables. Bulletin du Cancer. 103(3). 259–272. 4 indexed citations

14.

Huillard, Olivier, Jérôme Alexandre, & François Goldwasser. (2016). Treatment of Advanced Renal-Cell Carcinoma.. New England Journal of Medicine. 374(9). 888–888. 10 indexed citations

15.

Arrondeau, Jennifer, Olivier Huillard, Camille Tlemsani, et al.. (2015). Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Expert Opinion on Investigational Drugs. 24(5). 673–687. 7 indexed citations

16.

Coriat, Romain, Jérôme Alexandre, Carole Nicco, et al.. (2013). Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. Journal of Clinical Investigation. 124(1). 262–272. 64 indexed citations

17.

Coriat, Romain, Carole Nicco, Christiane Chéreau, et al.. (2012). Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo. Molecular Cancer Therapeutics. 11(10). 2284–2293. 170 indexed citations

18.

Hilgers, Werner, Sandrine Faivre, Jérôme Alexandre, et al.. (2006). A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Investigational New Drugs. 24(4). 311–319. 13 indexed citations

19.

Alexandre, Jérôme, Frédéric Batteux, Carole Nicco, et al.. (2006). Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel‐induced cancer cell death both in vitro and in vivo. International Journal of Cancer. 119(1). 41–48. 265 indexed citations

20.

Laurent, Alexis, Carole Nicco, Christiane Chéreau, et al.. (2005). Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species. Cancer Research. 65(3). 948–956. 422 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact